HomeBioPharma

BioPharma

BioPharma

Solid says early data suggest ‘differentiated’ Duchenne gene therapy

-

BioPharma

Biogen buys rights to Stoke’s rare epilepsy drug

BioPharma

FTC sues major pharmacy benefit managers over insulin prices

BioPharma

AstraZeneca, Daiichi’s Enhertu successor faces more questions after latest stumble

BioPharma

Biogen, UCB get the lupus data they’ve waited two decades for

BioPharma

‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public

0

BioPharma

Judge orders J&J to pay Auris investors more than $1B for merger violations

0

BioPharma

Lykos CEO to depart after FDA rejection, layoffs

0

BioPharma

BioMarin, having retrenched, outlines plans for growth

0

BioPharma

High-dose Spinraza meets study goal; Top Dyne executives exit

0

BioPharma

New research could ease concerns over suicide risk of obesity drugs

0

BioPharma

Script for success: The value of digital insights in pharma

0

1 2 34Page 4 of 4

Most Read

Solid says early data suggest ‘differentiated’ Duchenne gene therapy

Biogen buys rights to Stoke’s rare epilepsy drug

FTC sues major pharmacy benefit managers over insulin prices

Top 10 Companies in Biosimilars Production